Drugs / Cat-PAD

Trials 9

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01383590 Oct 2011 → Dec 2013 — Circassia Limited Completed No outcome recorded
Phase 1 NCT01383603 Oct 2011 → May 2014 — Circassia Limited Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00685711 Jan → Jul 2008 — Circassia Limited Completed No outcome recorded
Phase 24 trials
Phase 2 NCT02311413 Mar 2015 → Jul 2018 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT01921257 Aug 2013 → Dec 2015 allergic rhinitis Circassia Limited Completed No outcome recorded
Phase 2 NCT01033344 Jan → Sep 2010 — Circassia Limited Completed No outcome recorded
Phase 2 NCT00867906 Mar 2009 → Apr 2010 — Circassia Limited Completed No outcome recorded
Phase 32 trials
Phase 3 NCT02040844 Feb 2014 → May 2017 — Circassia Limited Completed No outcome recorded
Phase 3 NCT01620762 Oct 2012 → Jun 2016 allergic rhinitis Circassia Limited Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT00729508 Comparator Aug 2008 → Apr 2009 — Circassia Limited Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as Cat-PAD ClinicalTrials.gov intervention name — accepted as the source's own label NCT01033344 ↗
9

NCT01383590 ↗

NCT00729508 ↗

NCT02040844 ↗

NCT01921257 ↗

NCT00685711 ↗

NCT02311413 ↗

NCT01620762 ↗

NCT00867906 ↗

NCT01383603 ↗

Known as Cat Peptide Antigen Desensitisation “novel form of immunotherapy [Cat Peptide Antigen Desensitisation (Cat-PAD)]” PMID 29682277 ↗ Apr 2018
Modality Peptide “synthetic, allergen-derived peptide desensitising vaccine” NCT00685711 ↗
Route Other “Treatment will be administered as intradermal injections into the flexor surface of alternate forearms.” NCT00729508 ↗